Pfizer's bid to expand its oncology portfolio has suffered a setback with the news that the drugs giant has halted a late-stage trial of inotuzumab ozogamicin in patients with an aggressive form of non-Hodgkin's lymphoma due to futility ...more World News
Civil servants will be swapping the corridors of Whitehall for the NHS front line, Health Secretary Jeremy Hunt has announced.
...more UK News
Hard on the heels of Quintiles’ successful return to public ownership, US-based contract research organisation PRA International is sounding out prospects for its own initial public offering of common stock.
...more Clinical News
Pfizer's bid to expand its oncology portfolio has suffered a setback with the news that the drugs giant has halted a late-stage trial of inotuzumab ozogamicin in patients with an aggressive form of non-Hodgkin's lymphoma due to futility
Just as Elan Corp announced a range of transactions "designed to decisively transform and advance the company", long-time suitor Royalty Pharma has popped up again and raised its bid to acquire the Irish drugmaker
Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals of Norway in a deal valued at $700 million
Russia, Ukraine and Kazakhstan have recently taken steps to introduce drug reimbursement schemes which, if introduced, could completely change the operating environment for both their innovative drug and generic markets, says new research.
After a month of speculation, Actavis has announced it is buying Warner Chilcott in a stock-for-stock agreement worth $8.5 billion
The government has established a £260 million fund to help more National Health Service hospitals get up to speed with electronic prescription technologies and cut drug errors.
England’s National Institute for Health Research (NIHR) has launched a new campaign encouraging patients to ask their doctor about clinical-research opportunities.
The UK's Cell Therapy (CT) Catapult has now published its database of ongoing preclinical research in the field.
Geoff Frew, Managing Editor
